- Home
- OIA vs AVIR Comparison
OIA vs AVIR Comparison
Compare OIA & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OIA
- AVIR
- Stock Information
- Founded
- OIA 1988
- AVIR 2012
- Country
- OIA United States
- AVIR United States
- Employees
- OIA N/A
- AVIR N/A
- Industry
- OIA Finance Companies
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- OIA Finance
- AVIR Health Care
- Exchange
- OIA Nasdaq
- AVIR Nasdaq
- Market Cap
- OIA 269.4M
- AVIR 273.0M
- IPO Year
- OIA N/A
- AVIR 2020
- Fundamental
- Price
- OIA $5.60
- AVIR $3.39
- Analyst Decision
- OIA
- AVIR Hold
- Analyst Count
- OIA 0
- AVIR 1
- Target Price
- OIA N/A
- AVIR $6.00
- AVG Volume (30 Days)
- OIA 97.9K
- AVIR 413.2K
- Earning Date
- OIA 01-01-0001
- AVIR 08-06-2025
- Dividend Yield
- OIA 4.88%
- AVIR N/A
- EPS Growth
- OIA N/A
- AVIR N/A
- EPS
- OIA N/A
- AVIR N/A
- Revenue
- OIA N/A
- AVIR N/A
- Revenue This Year
- OIA N/A
- AVIR N/A
- Revenue Next Year
- OIA N/A
- AVIR N/A
- P/E Ratio
- OIA N/A
- AVIR N/A
- Revenue Growth
- OIA N/A
- AVIR N/A
- 52 Week Low
- OIA $4.93
- AVIR $2.46
- 52 Week High
- OIA $6.72
- AVIR $4.15
- Technical
- Relative Strength Index (RSI)
- OIA 34.55
- AVIR 51.38
- Support Level
- OIA $5.73
- AVIR $3.43
- Resistance Level
- OIA $5.75
- AVIR $3.83
- Average True Range (ATR)
- OIA 0.07
- AVIR 0.14
- MACD
- OIA -0.01
- AVIR -0.04
- Stochastic Oscillator
- OIA 0.00
- AVIR 15.19
About OIA Invesco Municipal Income Opportunities Trust
Invesco Muni Income Opps Trust operates as a diversified closed-end management investment company. Its investment objective is to provide a high level of current income which is exempt from federal income tax.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).